SCHEMBL24558178

SCHEMBL24558178

CC(C)(C)OC(=O)N1CCN2C(=O)c3cc(F)c(Br)cc3OC[C@H]2C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.39
IDO1 P14902 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
TP53 P04637 1/20 0.37
FPR2 P25090 2/20 0.36
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35
PBRM1 Q86U86 1/20 0.35
SCN9A Q15858 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
GPR119 Q8TDV5 2/20 0.35
KRAS P01116 1/20 0.34
DPP4 P27487 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
LMNA P02545 1/20 0.34
TRPV3 Q8NET8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26497692 0.90 USP30 (0.44) USP30IDO1HDAC6TP53FPR2
SCHEMBL30574275 0.90 USP30 (0.44) USP30IDO1HDAC6TP53FPR2
SCHEMBL24558288 0.90 LMNA (0.40) USP30IDO1HDAC6TP53FPR2
SCHEMBL23512534 0.89 USP30 (0.39) USP30HDAC6TP53FPR2SMARCA2
SCHEMBL26041621 0.89 USP30 (0.39) USP30HDAC6TP53FPR2SMARCA2
SCHEMBL23512857 0.89 USP30 (0.39) USP30HDAC6TP53FPR2SMARCA2
SCHEMBL29693184 0.89 USP30 (0.39) USP30HDAC6TP53FPR2SMARCA2
SCHEMBL31236075 0.88 SOS1 (0.41) USP30IDO1HDAC6FPR2SMARCA2
SCHEMBL31236101 0.88 SOS1 (0.41) USP30IDO1HDAC6FPR2SMARCA2
SCHEMBL30719820 0.88 SOS1 (0.41) USP30IDO1HDAC6FPR2SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents ASTRAZENECA AB (SE) 2025-09-09 US disclosed
CN-113508118-B Fused tricyclic compounds useful as anticancer agents 阿斯利康(瑞典)有限公司 2024-07-19 CN disclosed
EP-3935060-B1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2023-11-15 EP disclosed
EP-3935060-B1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2023-11-15 EP disclosed
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA UK LIMITED (GB) 2022-06-30 US disclosed
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA UK LIMITED (GB) 2022-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents MCL1, TP53, CCNA2 USP30 4265/4885IDO1 4481/4885HDAC6 797/4885
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS MCL1, TP53, CCNA2 USP30 4265/4885IDO1 4481/4885HDAC6 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.